StockNews.AISignal intelligence
Aquestive Therapeutics, Inc. · NASDAQ · Healthcare
Browse public AQST signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Aquestive Therapeutics disclosed positive human factors and pharmacokinetic validation results for its Anaphylm dibutepinephrine sublingual film. The data could de-risk development and aid regulatory discussions, though no dates or trial phases were provided. The near-term catalyst depends on subsequent regulatory milestones and potential timing for submissions.
View signal analysisAquestive Therapeutics has received a Complete Response Letter from the FDA regarding Anaphylm, its sublingual film for treating severe allergic reactions. This regulatory setback may hinder AQST’s growth and stock performance as investors reassess its prospects in the allergy treatment market.
View signal analysisThe FDA has declined to approve Aquestive Therapeutics' oral drug aimed at treating severe allergic reactions, which could significantly delay the product's market entry and affect the company's revenue forecasts. This decision casts a shadow on AQST's growth prospects, given its reliance on this drug for future sales.
View signal analysisAQST stock dropped 40.18% after FDA's notification of NDA deficiencies. FDA did not specify deficiencies but ongoing review is crucial. Aquestive plans to respond to FDA before January 31, 2026 deadline. Company has $120 million cash for Anaphylm approval process. ARS Pharmaceuticals urged FDA to delay AQST’s epinephrine approval.
View signal analysis